Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: An aptamer-drug conjugate for promising cancer therapy with comprehensive evaluation from rodents to non-human primates

Fig. 2

In vivo antitumor effect of Sgc8c-M in TNBC. a IHC characterization of PTK7 expression on tumor tissues of SUM159, MDA-MB-468, and TNBC PDX models. Scale bars, 20 μm. b Tumor volume and body weight of SUM159 tumor-bearing mice from a dose screening trial of Sgc8c-M (n = 4, one-way ANOVA). c, d, f Tumor growth curves for SUM159 (n = 4), MDA-MB-468 (n = 4, unpaired t test), and TNBC PDX (n = 5, unpaired t test) tumor-bearing mice after multiple dosing of 7 mg/kg Sgc8c-M (intravenous injection, i.v.), 10 mg/kg paclitaxel (intraperitoneal injection, i.p.), or 0.359 mg/kg MMAE (i.v.). e, g Tumor-killing effect study of Sgc8c-M in MDA-MB-468 (n = 3, unpaired t test) and TNBC PDX (n = 3, unpaired t test). Mice were given 7 mg/kg Sgc8c-M intravenously from day 0, and immunohistochemical characterization of CK19, Ki67, and pHH3 was performed at 48–96 h (48 h for MDA-MB-468, 96 h for TNBC PDX) at the end of administration. Scale bars, 20 μm. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01

Back to article page